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Summary
Background Although targeted biological treatments have transformed the outlook for patients with rheumatoid 
arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more than 
50% of patients with rheumatoid arthritis have low or absent CD20 B cells—the target for rituximab—in the main 
disease tissue (joint synovium), we hypothesised that, in these patients, the IL-6 receptor inhibitor tocilizumab would 
be more effective. The aim of this trial was to compare the effect of tocilizumab with rituximab in patients with 
rheumatoid arthritis who had an inadequate response to anti-tumour necrosis factor (TNF) stratified for synovial 
B-cell status.
Methods This study was a 48-week, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial 
(rituximab vs tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis; R4RA) done in 
19 centres across five European countries (the UK, Belgium, Italy, Portugal, and Spain). Patients aged 18 years or 
older who fulfilled the 2010 American College of Rheumatology and European League Against Rheumatism 
classification criteria for rheumatoid arthritis and were eligible for treatment with rituximab therapy according to 
UK National Institute for Health and Care Excellence guidelines were eligible for inclusion in the trial. To inform 
balanced stratification, following a baseline synovial biopsy, patients were classified histologically as B-cell poor or 
rich. Patients were then randomly assigned (1:1) centrally in block sizes of six and four to receive two 1000 mg 
rituximab infusions at an interval of 2 weeks (rituximab group) or 8 mg/kg tocilizumab infusions at 4-week intervals 
(tocilizumab group). To enhance the accuracy of the stratification of B-cell poor and B-cell rich patients, baseline 
synovial biopsies from all participants were subjected to RNA sequencing and reclassified by B-cell molecular 
signature. The study was powered to test the superiority of tocilizumab over rituximab in the B-cell poor population 
at 16 weeks. The primary endpoint was defined as a 50% improvement in Clinical Disease Activity Index (CDAI50%) 
from baseline. The trial is registered on the ISRCTN database, ISRCTN97443826, and EudraCT, 2012-002535-28.
Findings Between Feb 28, 2013, and Jan 17, 2019, 164 patients were classified histologically and were randomly 
assigned to the rituximab group (83 [51%]) or the tocilizumab group (81 [49%]). In patients histologically classified as 
B-cell poor, there was no statistically significant difference in CDAI50% between the rituximab group (17 [45%] of 
38 patients) and the tocilizumab group (23 [56%] of 41 patients; difference 11% [95% CI –11 to 33], p=0·31). However, 
in the synovial biopsies classified as B-cell poor with RNA sequencing the tocilizumab group had a significantly 
higher response rate compared with the rituximab group for CDAI50% (rituximab group 12 [36%] of 33 patients vs 
tocilizumab group 20 [63%] of 32 patients; difference 26% [2 to 50], p=0·035). Occurrence of adverse events (rituximab 
group 76 [70%] of 108 patients vs tocilizumab group 94 [80%] of 117 patients; difference 10% [–1 to 21) and serious 
adverse events (rituximab group 8 [7%] of 108 vs tocilizumab group 12 [10%] of 117; difference 3% [–5 to 10]) were not 
significantly different between treatment groups.
Interpretation The results suggest that RNA sequencing-based stratification of rheumatoid arthritis synovial tissue 
showed stronger associations with clinical responses compared with histopathological classification. Additionally, for 
patients with low or absent B-cell lineage expression signature in synovial tissue tocilizumab is more effective than 
rituximab. Replication of the results and validation of the RNA sequencing-based classification in independent 
cohorts is required before making treatment recommendations for clinical practice.
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Introduction
Rheumatoid arthritis is a chronic immune mediated 
inflammatory disease characterised by synovitis and joint 
damage that results in considerable morbidity and 
increased mortality.1 Biological disease modifying anti­
rheumatic drugs (DMARDs) have transformed the 
outlook for patients with rheumatoid arthritis; however, 
the absence of a meaningful response to treatment in 
approximately 40% of patients and the potential side­
effects and high cost of biological DMARDs have 
underlined the need to identify predictive markers 
of response to facilitate patient stratification before 
treatment and ensure the best therapeutic outcome.2
B cells are known to contribute to the pathogenesis of 
rheumatoid arthritis by driving synovial inflammation 
through the production of local disease specific autoanti­
bodies,3 secreting proinflammatory and osteoclastogenic 
cytokines,4 and acting as antigen presenting cells. The 
important role of B cells is also supported by the efficacy 
of the specific CD20 B­cell depleting drug, rituximab.5 
Rituximab is licensed for use in rheumatoid arthritis 
after unsuccessful conventional synthetic DMARDs and 
tumour necrosis factor (TNF) inhibitor therapy.
However, in this more therapy­resistant patient cohort, 
clinical response to rituximab is heterogeneous, with 
only 30% of patients reported to have a 50% improve ment 
in the American College of Rheumatology response 
criteria (ACR50) at 6 months.6 Given the mechanism of 
action of rituximab, it was hypothesised that the number 
of circulating B cells before and after treatment could be 
used to predict treatment response. However, pretreatment 
peripheral B­cell numbers or depletion levels, measured 
by conventional flow cytometry, found no association 
with clinical outcome.5–7 Moreover, although the depth of 
depletion measured by high­sensitive flow cytometry 
initially appeared to be more informative, small studies 
have reported contradictory results.8,9 Nevertheless, these 
studies have highlighted that a high number of circulating 
CD20 negative plasmablasts and preplasma cells was 
associated with non­response. However, the crucial ques­
tion remains unanswered: why—despite the profound 
depletion of peripheral blood B cells induced by rituximab 
in most patients—do only approximately half of patients 
respond to this therapy? How the number and depletion 
of B cells in the disease tissue (synovium) relates to 
rituximab response is also unclear. In that context, variable 
results from small, observational, biopsy­based studies 
have been reported.10–12 In particular, the number of 
synovial CD79a B cells reported before treatment,12 and 
the reduction of specific molecular signatures11 and 
synovial plasma cells after treatment10 have shown an 
association with response to rituximab. However, the 
observational nature of these studies, the small number of 
patients analysed, and the use of different timepoints for 
assessment of treatment outcome has made drawing firm 
conclusions difficult.
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Research in context
Evidence before this study
We searched PubMed for clinical trials, observational studies, 
and review articles with the search terms “rheumatoid arthritis”, 
“rituximab”, “B cells” or “B lymphocytes”, and “synovial 
membrane”. Articles published between June 1, 2010, and 
June 1, 2020, were considered for inclusion. Several post-hoc 
analyses of randomised clinical trials that investigated the use 
of peripheral blood biomarkers to predict response to rituximab 
were identified, but none of them proved effective for patient 
stratification in clinical practice. Only a few observational 
studies provided a direct analysis of the disease tissue (ie, the 
synovial membrane) before treatment with rituximab. 
Although specific cellular subpopulations and molecular 
signatures were found to be associated with response, no firm 
conclusions could be made in relation to the prediction of 
treatment response, mainly because of the small sample sizes 
and absence of randomisation.
Added value of this study
R4RA is the first biopsy-driven, multicentre, randomised trial 
comparing tocilizumab with rituximab in patients with 
rheumatoid arthritis who had inadequate responses to anti-
TNF drugs stratified for synovial B-cell status. Although there 
was no significant difference between the rituximab and the 
tocilizumab groups using histological B-cell classification for 
the primary endpoint, the study showed a significant difference 
in favour of tocilizumab in the number of patients with an 
improvement in Clinical Disease Activity Index (CDAI) by 50% 
or more and CDAI less than 10·1 (ie, low disease activity, defined 
as major treatment response; CDAI-MTR). Moreover, when 
classification was done with RNA sequencing, tocilizumab was 
superior to rituximab both for the primary outcome and 
CDAI-MTR. In patients who were classified as B-cell poor, 
tocilizumab was also superior to rituximab for most secondary 
outcomes.
 Implications of all the available evidence
The R4RA trial represents a milestone in the mechanistic 
investigation at the disease tissue level of the relationship 
between drug mode of action and clinical response. Compared 
with the current clinical approach, R4RA shows that in patients 
with low or absent of B cell expression signature in synovial 
tissue an alternative treatment—such as IL-6 receptor 
inhibition with tocilizumab—is superior to B-cell targeting with 
rituximab. Replication of the results and validation of 
RNA sequencing classification in independent cohorts might 
lead to the integration of molecular pathology into clinical 
algorithms to guide treatment allocation of target biological 
therapies according to drug target expression levels in the 
disease tissue.
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Of note, as previously shown in joint replacement 
tissue from late stage rheumatoid arthritis disease,13 and 
in active early rheumatoid arthritis14 more than 50% of 
patients show low or absent B­cell infiltration (B­cell 
poor) in the synovial biopsy, suggesting that in B­cell 
poor patients joint inflammation is driven by other 
cell types. This prompted us to use a randomised trial to 
test the hypothesis that in patients with low or absent of 
CD20 B cells in synovial biopsy rituximab would be less 
efficacious than an alternative targeting biological DMARD 
(eg, tocilizumab, a specific IL6­receptor inhibitor).
The aim of this study—the first biopsy­driven 
randomised clinical trial in rheumatoid arthritis—was 
to evaluate whether tocilizumab is superior to rituximab 
in improving clinical outcomes in patients with low 
absent of synovial B cells. The trial represents a mile­
stone, towards precision rheumatology,15 through its 
mechanistic investigation at the disease tissue level of 
the relationship between drug mode of action and 
clinical response.
Methods
Study design and participants
We did a phase 4, open­label, multicentre, randomised 
trial in 19 centres from five European countries: the UK, 
Belgium, Italy, Portugal, and Spain. The study was 
done in compliance with the Declaration of Helsinki, 
International Conference on Harmonisation Guidelines 
for Good Clinical Practice, and local country regulations. 
The final protocol, amendments, and documentation of 
consent were approved by the institutional review board 
of each study centre or relevant independent ethics 
committees. The study protocol has been published 
online.
Patients aged 18 years or older who fulfilled the 
2010 ACR and European League Against Rheumatism 
(EULAR) classification criteria for rheumatoid arthritis16 
and were eligible for treatment with rituximab therapy 
according to UK National Institute for Health and Care 
Excellence (NICE) guidelines (patients who had received 
previous unsuccessful treatment with or were intolerant 
to conventional synthetic DMARD therapy and at least 
one biological therapy, excluding the study drugs, 
rituximab and tocilizumab)17 were eligible for inclusion in 
the study. Patients were identified through rheumatology 
outpatient clinics at each study site. A full list of the 
inclusion and exclusion criteria is provided in the 
appendix (p 1). All patients provided written informed 
consent.
Randomisation and masking
At week 0, patients were randomly assigned (1:1) in block 
sizes of six and four to the rituximab group or the 
tocilizumab group stratified into four blocks according 
to histological classification of baseline synovial biopsy 
(B­cell poor, B­cell rich, germinal centre positive, or 
unknown) and by site (Queen Mary University London, 
London, UK vs all other sites) using an interactive web 
response system. The randomisation list and allocation 
algorithm were prepared by the trial statistician and 
securely embedded with the application code so that it 
was not accessible to end users. The programmer was 
responsible for implementing the allocation algorithm 
into the randomisation database. The trial manager and 
trial management team were responsible for checking 
patient eligibility and doing the randomisation pro­
cedure centrally. The randomisation result was sent 
electronically to all the clinical trial site staff by the trial 
office except the named joint assessor (research nurse or 
assistant) at each site, who remained masked to study 
drug allocation. All site teams remained masked to 
histological subtypes throughout the duration of the 
study.
Procedures
Patients underwent a synovial biopsy of a clinically active 
joint at entry to the trial. The biopsy was done according 
to local expertise, with either a US­guided or arthroscopic 
procedure as previously described.18,19 Six to eight biopsies 
were immediately fixed in 4% paraformaldehyde for 
paraffin embedding and an additional six immersed in 
RNA­Later (Ambion) for later RNA extraction and shipped 
to the Pathology Laboratory, Barts Health NHS Trust, 
London, UK, for processing and central evaluation, as per 
protocol standard operating procedure.
A minimum of six synovial biopsies were embedded 
in paraffin en masse and assessed histologically. The 
sections were then stained for haematoxylin and eosin 
and immune­histochemical markers (appendix p 13), 
as previously described.3,20 Sections underwent semi­
quantitative scoring to determine expression of CD20 
B cells, CD3 T cells, CD138 plasma cells, and CD68 lining 
and sublining macrophages (appendix p 13). The scoring 
process was adapted from a previously described and 
validated score.20–22 Following histological assessment of 
CD20 semi­quantitative scores, patients were classified 
as B­cell rich or B­cell poor at Barts Health NHS Trust 
by a consultant pathologist (HR), which was confirmed 
in an independent evaluation by a second expert in 
synovial pathology, according to a validated algorithm 
(appendix p 14). Synovial tissues with a CD20 score less 
than two were classified as B­cell poor; tissues with 
CD20 score of two to four and CD20 B­cell aggregates 
were classified as B­cell rich. Any discrep ancies in 
classification were resolved through mutual agreement 
(between HR and GT). Patients were classified as 
unknown if definite synovial tissue could not be iden­
tified. B­cell rich samples were classified as germinal 
centre positive if CD21 follicular dendritic cell networks 
were present (appendix p 14). As predefined in the study 
protocol, only patients classified as B­cell rich or B­cell 
poor were included in the primary analysis.
A minimum of six synovial samples per patient were 
immediately immersed in RNA­Later for RNA sequencing. 
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The RNA from these samples was extracted as described 
in the appendix (p 15)20 and sequenced at Genewiz 
(Bishop’s Stortford, UK) according to the standard 
operating procedure (appendix p 15). 184 paired­end 
RNA sequenced samples of 150 base pairs were trimmed 
to remove the Illumina adaptors with bbduk from the 
BBMap package (version 37.93) according to default 
parameters, using R (version 3.6.0). Transcripts were 
quantified using Salmon (version 0.13.1)23 and an index 
generated from the Gencode (release­29) transcriptome, 
in accordance with the standard operating procedure. 
Tximport (version 1.13.10) was used to aggregate the 
transcript level expression data, counts were then subject 
to variance stabilising transformation using DESEQ2 
(version 1.25.9).24 Patients were classified as B­cell poor or 
B­cell rich according to a previously developed B­cell 
specific gene module, derived from analysis of FANTOM5 
gene expression data.25 Because no predetermined cutoff 
points for B­cell transcript classification were found in the 
literature, patients were classified as B­cell poor or B­cell 
rich according to the median transcript module value to 
avoid potential bias (appendix p 15).
Following synovial biopsy and subsequent random 
assignment, patients in the rituximab group received 
two 1000 mg rituximab infusions 2 weeks apart. Patients 
in the tocilizumab group received 8 mg/kg tocilizumab 
monthly infusions. Both drugs were obtained from 
hospital stocks. Patients were followed up every 4 weeks 
throughout the 48­week trial treatment period during 
which clinical and safety data were collected (appendix 
p 17). Clinical outcomes up to week 16 are presented 
herein.
Outcomes
The primary endpoint was the difference in Clinical 
Disease Activity Index (CDAI)26 by 50% or more 
improvement (CDAI50%) rate at 16 weeks between the 
tocilizumab group and rituximab group in the intention­
to­treat population. Primary efficacy analysis evaluated 
the number of patients meeting the primary endpoint. 
Patients could be deemed non­responders (predefined in 
the protocol) if they had CDAI50% but did not have low 
disease activity, with a CDAI of less than 10·1 (CDAI­major 
treatment response; CDAI­MTR); thus, a supplementary 
efficacy analysis in line with the International Council for 
Harmonisation Guidelines (2019) was done to evaluate 
the number of patients meeting CDAI­MTR. In addition, 
as predefined in the protocol, an aim of the trial was 
also to test both cellular and molecular signatures in 
the synovial tissue; therefore, CDAI50% and CDAI­MTR 
were also evaluated in patients classified according to the 
RNA sequencing.
The study was not powered to evaluate comparative 
efficacy of either drug in the B­cell rich cohort; however, 
assessment of CDAI50% response and CDAI­MTR at 
16 weeks was done as a supplementary analysis where 
the response rate of rituximab was compared with 
toci lizumab. Additional secondary efficacy analyses 
included assessment of CDAI remission; Disease Activity 
Score (DAS28)­erythrocyte sedi mentation rate (ESR) 
and DAS28­C reactive protein (CRP) moderate or good 
EULAR response; DAS28­ESR and DAS28­CRP low­
disease activity; DAS28­ESR and DAS28­CRP remission; 
and patient reported outcomes, such as fatigue (appendix 
p 2). In addition, to assess the performance of the RNA 
sequencing stratification method, as a post­hoc analysis 
we evaluated the RNA sequencing FANTOM5 B cell 
module by varying the cutoff between B­cell rich and 
B­cell poor tissue to determine whether the median value 
was optimal (appendix p 16). The CDAI50% rates of 
response in patients classified as anti­citrullinated protein 
antibodies (ACPA) and rheumatoid factor (RF) positive 
and negative were compared in a post­hoc analysis.
The incidence and severity of treatment and 
procedure emergent adverse events were monitored 
throughout the study; adverse event coding was done 
according to the Medical Dictionary for Regulatory 
Activities (version 22). The causality and expectedness 
of all serious adverse events in relation to the trial 
treatment was assessed by the principal investigator 
(or delegated medic), according to the severe adverse 
event definition. If a severe adverse event related to the 
treatment was unexpected it was considered a suspected 
unexpected serious adverse reaction. All severe adverse 
events up to week 48 (and up to 30 days later) were 
reported by relatedness using the Medical Dictionary 
for Regulatory Activities lowest level term classification. 
All adverse events up to week 48 (and up to 30 days 
later) were reported using the Medical Dictionary for 
Regulatory Activities system organ class classification. 
Recurrent events (events that occurred more than once 
in the same participant) were considered as one event.
Statistical analysis
A sample size of 82 patients who were B­cell poor was 
needed to provide 90% power to detect a 35% difference 
(assuming 55% response rate to tocilizumab and 20% to 
rituximab (unpublished data) in patients classified as 
responders by the primary endpoint. The assumed 
proportion of patients recruited who were B­cell poor 
was 60%, B­cell rich was 35%, and germinal centre 
positive was 5%. After estimating that 10% of biopsy 
samples would be ungradable and assuming a 5% drop­
out rate, a total of 160 patients would be required to 
recruit 82 patients who were B­cell poor. No power 
calculation was done for patients who were B­cell rich.
The primary endpoint and other binary endpoints were 
analysed using a χ² or Fisher’s exact test. For continuous 
outcomes, an analysis of covariance (ANCOVA) was 
done, with treatment as factor and baseline value as 
the continuous covariate. When the assumptions for 
the ANCOVA were not met, non­parametric ANCOVA 
was used. Changes from baseline within groups were 
analysed with a paired Wilcoxon test.
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Although the study was not powered to evaluate 
comparative efficacy of either drug in patients who were 
B­cell rich, we tested whether rituximab was as efficacious 
as tocilizumab as a secondary analysis. The analysis of 
the interaction between treatments and pathotypes was 
done through the likelihood ratio test between two nested 
logistic regression models: one with pathotype and 
treatment as covariates and the other with pathotype, 
treatment, and their interaction as covariates.
All efficacy analyses were done in the intention­to­treat 
population and then on the per­protocol set to assess the 
robustness of the results. The per­protocol population 
included all patients from the intention­to­treat popula­
tion who did not have any major protocol violations 
(appendix p 12). The list of deviations that excluded a 
patient from the per­protocol population was reviewed at a 
classification meeting before the data lock. Safety analyses 
were done on the safety population (intention­to­treat 
Figure: Trial profile
*Six patients did not have suitable joints at biopsy and one for clinical reasons unrelated to rheumatoid arthritis.
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79 B-cell poor patients 64 B-cell rich patients 9 germinal centre positive patients 
167 underwent synovial biopsy  
212 patients assessed for eligibility
9 with unknown histology
22 excluded
9 did not meet inclusion criteria
6 declined to participate
7 did not respond
190 provided informed consent
23 excluded
10 did not meet inclusion criteria
6 declined to continue
7 for other reasons*
3 did not meet inclusion criteria
164 randomly assigned
3 did not receive the study drug
 2 declined to continue 
 1 lost to follow up
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population, including participants who received at least 
one dose of the trial medication). In the safety analysis, 
patients were analysed according to their actual treatment 
in case this differed from the scheduled treatment 
(randomised or switched). Missing values assumed to 
be missing at random were imputed using Multiple 
Imputation by Chained Equations and implemented 
using Amelia (version 1.7.5; R package).
All statistical analyses were done using R (version 3.5.1). 
The trial is registered on the ISRCTN database, 
ISRCTN97443826, and EudraCT, 2012­002535­28. An 
independent Data Monitoring Ethics Committee met 
every 6 months during the trial to review the accruing 
trial data, assess whether there were any safety issues, 
and to make recommendations to the trial steering 
committee.
Role of the funding source
Funding for this study was provided by the Efficacy and 
Mechanism Evaluation programme of the National 





















Female 128 (80%) 62 (76%) 66 (84%) 0·21 69 (87%) 32 (84%) 37 (90%) 0·42 50 (78%) 23 (70%) 27 (87%) 0·092
Male 33 (20%) 20 (24%) 13 (16%) 0·21 10 (13%) 6 (16%) 4 (10%) 0·42 14 (22%) 10 (30%) 4 (13%) 0·092



































































































RF or ACPA 
positive
140 (87%) 73 (89%) 67 (85%) 0·42 67 (85%) 34 (89%) 33 (80%) 0·26 55 (86%) 28 (85%) 27 (87%) 0·79
RF positive 119 (74%) 64 (78%) 55 (70%) 0·22 55 (70%) 29 (76%) 26 (63%) 0·21 49 (77%) 26 (79%) 23 (74%) 0·66


































































DAS28-ESR 5·81 (1·25) 5·84 (1·19) 5·78 (1·31) 0·74 5·88 (1·10) 5·80 (1·04) 5·95 (1·17) 0·56 5·85 (1·32) 5·76 (1·41) 5·94 (1·23) 0·581














































































































161 (100%) 82 (100%) 79 (100%) NA 79 (100%) 38 (100%) 41 (100%) NA 64 (100%) 33 (100%) 31 (100%) NA
(Table 1 continues on next page)
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Institute for Health Research (NIHR). The funder of the 
study had no role in study design, data collection, data 
analysis, data interpretation, or writing of the Article. 
No industry funding was implicated in this study.
Results
Between Feb 28, 2013, and Jan 17, 2019, 212 patients were 
screened, of whom 190 (89%) gave consent, 167 (79%) had 
synovial biopsies, and 164 (77% [131 women]) were 
randomly assigned to one of the two treatment groups. 
Three patients were randomly assigned, but did not receive 
study drug (individuals were not included in the intention­
to­treat analysis). The trial ended as recruitment targets 
were reached. After synovial biopsies were classified, 
83 (50%) patients were randomly assigned to the rituximab 
group and 81 (50%) to the tocilizumab group. 81 (99%) of 
the 82 patients from the rituximab group and 73 (92%) of 
the 79 patients in the tocilizumab group completed 
treatment to primary endpoint at week 16 (figure). 62 (38%) 
of the 164 included patients were recruited at Barts Health 
NHS Trust (appendix p 3).
Baseline characteristics, disease activity, and histological 
groups are reported in table 1 and the appendix (pp 4–5). 
79 (49%) of 161 patients were histologically classified as 
B­cell poor, 64 (40%) patients were B­cell rich, 9 (6%) were 
germinal centre positive, and 9 (6%) were unknown. Of 
the 79 (49%) of 161 patients classified as B­cell poor, 
38 (48%) were assigned to the rituximab group and 
41 (52%) to the tocilizumab group.
At 16 weeks in the B­cell poor population, there was no 
statistically significant difference in rate of CDAI50% 
response between the rituximab group (17 [45%] of 
38 patients) and the tocilizumab group (23 [56%] of 
41 patients; difference 11% [95% CI –11 to 33], p=0·31; 
table 2). However, a predefined supplementary analysis 
of CDAI­MTR did show a statistical significance between 
the rituximab group (9 [24%] of 38 patients) and the 
tocilizumab group (19 [46%] of 41 patients; differ­
ence 22% [2 to 43], p=0·035; table 2). In addition, the 
response rates in the B­cell poor patients in the 
tocilizumab group were statistically significantly higher 
for a number of secondary endpoints (table 2).
Quality of life outcome measures (Functional 
Assessment of Chronic Illness Therapy/36­Item Short 
Form Health Survey scores) improved more between 
baseline and 16 weeks in the tocilizumab group (table 2). 
We observed little difference in Health Assessment 
Questionnaire scores between the rituximab group and 
the tocilizumab group (table 2). Of note, per­protocol 
analyses were consistent with intention­to­treat outcomes 
(appendix p 6).
Of the 162 patients with RNA available for extraction, 
nine (6%) patients were excluded after histological 
classification as germinal centre positive, one (1%) patient 
withdrew before drug administration, and 28 (17%) patients 
were excluded because of RNA sequencing quality 
con trol or poor mapping. 124 (77%) patients had RNA 
sequencing data available for analysis (appendix p 15); 
65 (52%) of whom were classified as B­cell poor. The 
tocilizumab group had a significantly higher response rate 
compared with the rituximab group for both CDAI50% 
(rituximab group 12 [36%] of 33 patients vs tocilizumab 
group 20 [63%] of 32 patients; diff erence 26% [95% CI 
2–50], p=0·035) and for CDAI­MTR (rituximab group 
4 [12%] of 33 patients vs tocilizumab group 16 [50%] 
of 32 patients; diff erence 38% [17–59], p=0·0012). The 
response rates for a number of secondary outcomes 
were also significantly higher in the tocilizumab group 
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Data are n (%), median [IQR], or mean (SD). ACPA=anti-citrullinated protein antibody. CRP=C-reactive protein. DAS28=28 joint count Disease Activity Score. ESR=erythrocyte sedimentation rate. RF=rheumatoid 
factor. NA=not applicable. SHSS=Sharp van der Heijde score. TNF=tumour necrosis factor. *Eight patients in total used non-TNF inhibitor biological drugs (seven received abatacept and one received vaccine 
RA TNF-K-006 for a clinical study). †p values refer to the χ² comparing the number of biological drugs used in rituximab and tocilizumab groups.
Table 1: Baseline characteristics of patients, stratified by histological classification and investigational medicinal product
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compared with the rituximab group (table 2). Per­protocol 
analyses were consistent with the intention­to­treat results 
(appendix p 7).
64 (40%) of the 161 patients categorised histologically 
and 59 (47%) of the 124 patients categorised with 
RNA sequencing were classified as B­cell rich. Although 
the study was not powered for the comparative analysis 
of B­cell rich populations in each treatment group, we 
observed similar week 16 response rates between the 
rituximab group and the tocilizumab group for most 
of the endpoints analysed, including CDAI50% and 
CDAI­MTR (table 3). Similar effects were seen for a 
number of additional secondary endpoints (table 3). Of 
note, compared with the analysis in the B­cell poor 
population, there were minimal differences in quality of 
life measures between the rituximab and tocilizumab 
groups (table 3). Per­protocol analyses were consistent 
with the intention­to­treat results (appendix pp 8–9).
Logistic regression analysis showed no evidence of an 
interaction between either study drug and histologically 
defined B cell subgroups for primary endpoint, but 
a statistically significant interaction between RNA 
sequencing­defined B cell subgroup and the study drugs 
was reported (p=0·049) when using CDAI­MTR. 
However, when differences in CDAI50% response rates 
to rituximab between patients classified histologically as 
B­cell rich or B­cell poor were evaluated, no statistically 
significant differences in outcome (p=0·81) were 
reported.
In the rituximab there was no statistically significant 
difference in CDAI50% response rates between those 
classified as ACPA­positive (30 [45%] of 67 patients) and 
ACPA­negative (7 [46%] of 15 patients, p=0·89] and 
between patients classified as RF­positive (28 [43%] of 
64 patients) and RF­negative (9 [50%] of 18 patients, 
p=0·63; appendix p 10). There was also no significant 
difference in response rates according to RF and ACPA 
seropositive patients treated with tocilizumab (appendix 
p 10).
Safety data up to 48 weeks are summarised in table 4 
and in the appendix (p 11). Occurrence of adverse events 
(rituximab group 76 [70%] of 108 patients vs tocilizumab 
group 94 [80%] of 117 patients; difference 10% [95% CI 
–1 to 21]) and serious adverse events (rituximab group 
8 [7%] of 108 patients vs tocilizumab group 12 [10%] of 
117 patients; difference 3% [–5 to 10]) was not significantly 
different between treatment groups. One death due 
to suicide was reported in the rituximab group. No 
malignancies were reported within the 48­week trial 
period. Two patients in the rituximab group (corneal 
melt [reported as a suspected unexpected serious adverse 
reaction] and suicide) and three patients in the 


















CDAI ≥50% improvement at week 16 17 (45%) 23 (56%) 11% (–11 to 33) 0·31 12 (36%) 20 (63%) 26% (3 to 50) 0·035
Supplementary endpoint*
CDAI ≥50% improvement and CDAI ≤10·1 at week 16 9 (24%) 19 (46%) 23% (2 to 43) 0·035 4 (12%) 16 (50%) 38% (17 to 59) 0·0012
Binary secondary endpoints*
CDAI ≤10·1 at week 16 11 (29%) 19 (46%) 17% (–3 to 38) 0·11 5 (15%) 16 (50%) 35% (14 to 56) 0·0036
DAS28-ESR ≤3·2 at week 16 10 (26%) 18 (44%) 18% (–4 to 38) 0·10 6 (18%) 17 (53%) 35% (13 to 57) 0·0032
DAS28-CRP ≤3·2 at week 16 12 (32%) 19 (46%) 15% (–7 to 36) 0·18 7 (21%) 16 (50%) 29% (7 to 51) 0·015
DAS28-ESR ≤2·6 at week 16 6 (16%) 15 (37%) 21% (2 to 40) 0·037 3 (9%) 13 (41%) 32% (12 to 51) 0·004
DAS28-CRP ≤2·6 at week 16 7 (18%) 13 (32%) 13% (–6 to 32) 0·17 4 (12%) 10 (31%) 19% (0 to 39) 0·076
Moderate or good EULAR DAS28-ESR response at week 16 25 (66%) 36 (88%) 22% (4 to 40) 0·031 21 (64%) 30 (94%) 30% (12 to 49) 0·0053
Moderate or good EULAR DAS28-CRP response at week 16 22 (58%) 32 (78%) 20% (0 to 40) 0·054 18 (55%) 27 (84%) 30% (9 to 51) 0·015
Continuous secondary endpoints†
CDAI, least squares mean change at week 16 –12·1 (1·9) –15·7 (1·9) 3·6 (–1·7 to 8·9) 0·18 –10·9 (2·0) –17·2 (2·0) 6·3 (0·7 to 12·0) 0·029
DAS28-ESR, least squares mean change at week 16 –1·5 (0·2) –2·6 (0·2) 1·1 (0·5 to 1·7) 0·0006 –1·3 (0·2) –2·8 (0·2) 1·5 (0·9 to 2·2) <0·0001
DAS28-CRP, least squares mean change at week 16 –1·3 (0·2) –2·0 (0·2) 0·7 (0·1 to 1·3) 0·032 –1·1 (0·2) –2·1 (0·2) 1·0 (0·4 to 1·6) 0·0021
HAQ, least squares mean change at week 16 –0·3 (0·1) –0·4 (0·1) 0·1 (–0·1 to 0·3) 0·40 –0·2 (0·1) –0·2 (0·1) <0·1 (–0·2 to 0·2) 0·91
FACIT, least squares mean change at week 16 1·6 (1·1) 5·6 (1·1) –4·0 (–7·2 to -0·8) 0·015 2·1 (1·4) 4·9 (1·4) –2·8 (–6·9 to 1·2) 0·16
SF36-PCS, least squares mean change at week 16 4·1 (1·5) 7·3 (1·5) –3·2 (–7·4 to 0·9) 0·12 3·5 (1·5) 4·3 (1·5) –0·8 (–5·0 to 3·5) 0·72
SF36-MCS, least squares mean change at week 16 –0·7 (1·6) 2·1 (1·6) –2·8 (–7·3 to 1·8) 0·22 0·9 (1·8) 4·5 (1·9) –3·7 (–8·8 to 1·5) 0·16
Data are n (%) or least squares mean (SD), unless otherwise specified. Patients classified histologically are compared with those categorised with RNA sequencing. CDAI=Clinical Disease Activity Index. 
CRP=C-reactive protein. DAS28=28 joint count Disease Activity Score. EULAR=European League against Rheumatism. ESR=erythrocyte sedimentation rate. FACIT=Functional Assessment of Chronic Illness 
Therapy. HAQ=Health Assessment Questionnaire. SF36-MCS=Mental Components Summary of the SF-36 questionnaire. SF36-PCS=Physical Components Summary of the SF-36 questionnaire. SF36=36-Item 
Short Form Health Survey. *Treatment effect measured with percentage difference (95% CI). †Treatment effect measured with least squares mean (95% CI).
Table 2: Clinical outcomes at 16 weeks in the intention-to-treat B-cell poor population
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tocilizumab group (pleural effusion, chest pain, and 
cytokine release syndrome) discontinued the study 
regimens because of serious adverse events. Three 
patients were randomly assigned, but did not receive 
study drug; no serious adverse events were reported in 
these patients. Of note, there were no serious adverse 
events reported related to synovial biopsy.
Discussion
Rituximab remains an important therapeutic option for 
patients with rheumatoid arthritis; however, clinical 
response remains heterogeneous, with only 30% of 
patients with an inadequate response to anti­TNF reported 
to have an ACR50 response at 6 months.6 The mechanism 
of response and non­response remains unknown. Thus, 
understanding these mechanisms is crucial to avoid 
unnecessary exposure to a potentially toxic drug and delay 
in bringing disease under control. Because more than 
50% of patients with rheumatoid arthritis show low or 
absent B­cell infiltration in the main disease tissue (joint 
synovium), the rituximab versus tocilizumab in anti­TNF 
inadequate responder patients with rheumatoid arthritis 
(R4RA) trial was designed and independently supported 
by the UK NIHR to determine whether target expression 
levels (CD20 B cells) and B­cell associated molecular 
signatures in the synovial tissue can provide a mechanistic 
explanation for drug mode of action and treatment 
response.
In this first biopsy­based, multicentre, randomised 
controlled trial in rheumatoid arthritis, we tested the 
hypothesis that, in patients stratified for low or absent 
synovial­biopsy CD20 B cells—the target for rituximab—
tocilizumab, a specific IL­6­receptor inhibitor, would be 
superior. In patients classified as B­cell poor by histological 
classification, there was no statistically significant dif­
ference between the two treatment groups for the primary 
endpoint: CDAI50%. However, tocilizumab was superior 
to rituximab in patients with low disease activity, defined 
as CDAI50% and CDAI­MTR (CDAI <10·1).
In addition, when patients were classified as B­cell 
poor or B­cell rich by RNA sequencing, both the primary 
endpoint and CDAI­MTR reached statistical signifi­
cance in the B­cell poor group. The statistically 
significant interaction between RNA sequencing and 
the study drugs observed with CDAI­MTR suggests that 
the treatment effect difference between rituximab and 
tocilizumab was statistically different between the 
RNA sequencing­stratified B­cell poor and B­cell rich 
groups.
The reasons for the histological and RNA sequencing 
differences are likely to relate to the sensitivity of the 
classification technique. CD20 staining was evaluated at 











Treatment effect Unadjusted 
p value
Primary endpoint*
CDAI ≥50% improvement at week 16 13 (39%) 16 (52%) 12% (–12 to 37) 0·33 15 (50%) 14 (48%) –2% (–27 to 24) 0·89
Supplementary endpoint*
CDAI ≥50% improvement and CDAI ≤10·1 at week 16 5 (15%) 11 (36%) 20% (–1 to 41) 0·085 7 (23%) 9 (31%) 8% (–15 to 30) 0·51
Binary secondary endpoints*
CDAI ≤10·1 at week 16 7 (21%) 12 (39%) 18% (–5 to 40) 0·13 10 (33%) 10 (35%) 1% (–23 to 25) 0·93
DAS28-ESR ≤3·2 at week 16 8 (24%) 13 (42%) 18% (–5 to 40) 0·13 9 (30%) 10 (35%) 5% (–19 to 28) 0·71
DAS28-CRP ≤3·2 at week 16 12 (36%) 13 (42%) 6% (–18 to 30) 0·65 14 (47%) 11 (38%) –9% (–34 to 16) 0·50
DAS28-ESR ≤2·6 at week 16 2 (6%) 11 (36%) 29% (11 to 48) 0·0047 3 (10%) 10 (35%) 25% (4 to 45) 0·03
DAS28-CRP ≤2·6 at week 16 4 (12%) 9 (29%) 17% (–3 to 36) 0·12 4 (13%) 8 (28%) 14% (–6 to 35) 0·21
Moderate or good EULAR DAS28-ESR response at week 16 25 (76%) 27 (87%) 11% (–8 to 30) 0·34 24 (80%) 24 (83%) 3% (–17 to 23) 1·00
Moderate or good EULAR DAS28-CRP response at week 16 23 (70%) 25 (81%) 11% (–10 to 32) 0·31 23 (77%) 23 (79%) 3% (–19 to 24) 0·81
Continuous secondary endpoints†
CDAI, least squares mean change at week 16 –13·2 (2·1) –14·2 (2·1) 1·0 (–4·9 to 6·8) 0·73 –15 (2·1) –14·1 (2·2) –0·5 (–6·5 to 5·6) 0·88
DAS28-ESR, least squares mean change at week 16 –1·5 (0·2) –2·6 (0·2) 1·1 (0·5 to 1·8) 0·0009 –1·7 (0·2) –2·4 (0·2) 0·7 (0·1 to 1·4) 0·026
DAS28-CRP, least squares mean change at week 16 –1·5 (0·2) –2·0 (0·2) 0·6 (–0·0 to 1·1) 0·059 –1·7 (0·2) –1·9 (0·2) 0·3 (–0·3 to 0·9) 0·34
HAQ, least squares mean change at week 16 –0·3 (0·1) –0·4 (0·1) 0·1 (–0·2 to 0·4) 0·41 –0·3 (0·1) –0·5 (0·1) 0·2 (–0·0 to 0·5) 0·085
FACIT, least squares mean change at week 16 8·5 (1·9) 7·8 (2·0) 0·7 (–4·8 to 6·3) 0·79 6·9 (1·8) 8·34 (1·9) –1·5 (–6·7 to 3·8) 0·58
SF36-PCS, least squares mean change at week 16 7·0 (2·0) 8·5 (2·1) –1·5 (–7·2 to 4·2) 0·59 6·9 (1·9) 10·9 (2·1) –4·0 (–9·6 to 1·6) 0·16
SF36-MCS, least squares mean change at week 16 5·4 (2·2) 3·3 (2·4) 2·1 (–4·5 to 8·5) 0·53 4·4 (2·3) 3·01 (2·5) 1·4 (–5·4 to 8·2) 0·68
Data are n (%) or least squares mean (SD), unless otherwise specified. Patients classified histologically are compared with those categorised with RNA sequencing. CDAI=Clinical Disease Activity Index. 
CRP=C-reactive protein. DAS28=28 joint count Disease Activity Score. EULAR=European League against Rheumatism. ESR=erythrocyte sedimentation rate. FACIT=Functional Assessment of Chronic Illness 
Therapy. HAQ=Health Assessment Questionnaire. SF36-MCS=Mental Components Summary of the SF-36 questionnaire. SF36-PCS=Physical Components Summary of the SF-36 questionnaire. SF36=36-Item 
Short Form Health Survey. *Treatment effect measured with percentage difference (95% CI). †Treatment effect measured with least squares mean (95% CI).
Table 3: Clinical outcomes at 16 weeks in the intention-to-treat B-cell rich population
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three cutting levels on a minimum of six biopsies, which 
is recommended for use in clinical trials and reported to 
be representative of the whole joint tissue.27 Although the 
semi­quantitative score used for balanced stratification 
(before randomisation) had been validated both against 
digital image analysis and the transcript concentrations, 
determined using the FANTOM5­derived B­cell related 
gene set,20,25 because no published gold standard is 
available, the cutoff of 0–1 for B­cell poor classification 
and 2–4 for B­cell rich classification was set arbitrarily 
on the basis of a previous pilot study and might not have 
been at an optimal level for the whole trial. Furthermore, 
considering that these cutoffs were determined by 
physically counting the number of CD20 B cells, 
miscounting had the potential for misclassification.
Classification with RNA sequencing was determined 
by applying a FANTOM5­derived module, which 
includes 73 genes associated with B cells.20,25 Additionally, 
the six biopsied were homogenised and pooled to 
provide a more integrated measure (expression of 
30 000 genes) of pathobiological processes within the 
entire active joint and arguably a more precise estimate 
of the number of mature CD20 B cells and B cells at 
different stages of differentiation (eg, plasmablast and 
preplasma cells). Because plasmablast and preplasma 
cells, both in the peripheral blood and synovial tissue, 
have been shown to influence response to rituximab,9–12 
the RNA sequencing classification clearly appears to 
be more sensitive. In addition, the application of 
RNA sequencing classification overcame a number of 
limitations associated with histological classification, 
including the replacement of subjective assessments of 
synovial B­cell infiltration by histopathology with an 
objective method using the median transcript expression 
levels of a B­cell gene set module. Of note, in a post­hoc 









Serious adverse events 20 (9%) 8 (7%) 12 (10%) 3% (–5 to 10)
Serious adverse events related to study drug 12 (5%) 4 (4%) 8 (7%) 3% (–3 to 9)
Abdominal pain 1 (<1%) 1 (1%) 0 NA
Chest pain* 1 (<1%) 0 1 (1%) NA
Chronic obstructive pulmonary disease exacerbation 1 (<1%) 1 (1%) 0 NA
Corneal melt* 1 (<1%) 0 1 (1%) NA
Cytokine release syndrome† 1 (<1%) 1 (1%) 0 NA
Dental cyst 1 (<1%) 0 1 (1%) NA
Diarrhoea 1 (<1%) 1 (1%) 0 NA
Lower respiratory tract infection 1 (<1%) 0 1 (1%) NA
Leg pain 1 (<1%) 0 1 (1%) NA
Pilonidal sinus 1 (<1%) 0 1 (1%) NA
Pneumonia 1 (<1%) 0 1 (1%) NA
Urinary tract infection 1 (<1%) 0 1 (1%) NA
Serious adverse events unrelated to study drug 14 (6%) 4 (4%) 10 (9%) 5% (–1 to 11)
Chest pain 2 (1%) 1 (1%) 1 (1%) 0% (–3 to 2)
Chest pain (cardiac) 1 (<1%) 0 1 (1%) NA
Coronary angiogram 1 (<1%) 0 1 (1%) NA
Drainage of pilonidal abscess 1 (<1%) 1 (1%) 0 NA
Hallux valgus 1 (<1%) 0 1 (1%) NA
Parathyroid adenoma 1 (<1%) 0 1 (1%) NA
Pleural effusion† 1 (<1%) 0 1 (1%) NA
Seizure 1 (<1%) 0 1 (1%) NA
Suicide† 1 (<1%) 1 (1%) 0 NA
Toe amputation 1 (<1%) 0 1 (1%) NA
Total knee replacement 1 (<1%) 1 (1%) 0 NA
Urinoma 1 (<1%) 0 1 (1%) NA
Serious adverse events resulting in study drug discontinuation 5 (2%) 2 (3%) 3 (3%) 1% (–3 to 5)
Any non-serious adverse event 170 (76%) 76 (70%) 94 (80%) 10% (–1 to 21)
Data are n (%). All events reported after the first prescription of the study drug up to week 48 (+30 days). Some patients had more than one adverse event. Events are 
classified using the Medical Dictionary for Regulatory Activities system classification, using the lowest level terms grouping. No cancer was observed during the treatment 
period. However, there was one kidney carcinoma after week 48. NA=not applicable. *Event was a suspected unexpected serious adverse reaction. †Event led to treatment 
drug discontinuation.
Table 4: Safety data from baseline to 48 weeks
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were confirmed to have performed optimally because 
varying the cutoffs across a 20% range made no 
difference to results of the study based on the primary 
outcome measure.
In patients classified as B­cell poor by RNA sequencing, 
tocilizumab was significantly superior to rituximab not 
only in relation to CDAI50% and CDAI­MTR but also in 
most of the secondary endpoints considered, which 
suggests a closer association with a broad range of 
outcome measures. However, in patients classified as 
B­cell rich by RNA sequencing the efficacy of rituximab 
overlapped with tocilizumab suggesting that target 
expression levels in the disease tissue are important 
mechanistically in determining non­response and 
response. Namely, in patients classified as B­cell poor, 
tocilizumab is more efficacious at inhibiting non­B­cell 
dependent pathways (eg, IL­6), whereas in patients 
classified as B­cell rich, tocilizumab and rituximab are 
similarly efficacious at modulating B cell function.
This study also highlighted the potential importance of 
synovial biopsy in relationship to clinical response and 
RF and ACPA serological status because no statistically 
significant difference in clinical response rates to 
rituximab or tocilizumab were reported between patients 
who were positive and those who were negative for RF 
and ACPA. Thus, it is possible that the synovial biopsy 
might be more sensitive than serology in stratifying 
patients to rituximab therapy because—although there 
is a strong association between RF and ACPA positivity 
and B­cell rich synovitis14—there are some patients who 
are RF and ACPA positive but have low or absent B cells 
in the joint. However, these results must be interpreted 
with caution considering the small number of patients 
who were seronegative in the trial, with a potential for a 
false­negative finding; most studies have reported better 
response to rituximab in patients who are RF and ACPA 
positive.28
Regarding safety, although a higher number of serious 
adverse events and adverse events were reported in the 
tocilizumab group, these appeared largely unrelated to 
study drug, and there was no statistically significant 
difference between the two groups. Of note, there were 
no serious adverse events related to the synovial biopsy 
supporting previous data confirming the safety of mini­
mally invasive ultrasound­guided procedure done by 
rheumatologists.18
The study had some inevitable limitations. First, the 
potentially inaccurate binary B­cell poor or B­cell rich 
histological classification. Resolution of this issue will 
require analysis of the trial to determine a precise cutoff 
or a different classification method (eg, using continuous 
variable data, such as transcript concentrations) that is a 
sensitive predictive tool of clinical response marker for 
other therapeutic targets (eg, PD1).29 Second, the choice 
of tocilizumab as an active comparator to rituximab 
might not have been optimal because tocilizumab itself 
modulates B­cell function and survival.30 Third, the study 
design, with no drug allocation double­blinding, might 
have favoured the faster acting tocilizumab, given as 
monthly infusion, compared with rituximab, given 
every 6 months. However, because no study drug 
funding was provided, tocilizumab was the only choice 
available according to NICE guidance, and the Ethics 
Committee advised against double­blinding the trial 
because it would be impractical and extremely incon­
venient for patients. Fourth, despite the washout period 
for TNF inhi bitors and standardisation of steroid and 
conventional synthetic DMARD therapy at trial entry, 
it is possible that baseline resistant and responsive 
pathways were modulated heterogeneously by previous 
or concomitant therapy. Finally, the choice of an 
improvement of CDAI50% as a primary binary outcome, 
rather than EULAR­DAS28­ESR response, illustrates 
the different sensitivity of the avail able assessments 
methods. EULAR­DAS28­ESR response would have led 
to meeting the primary outcome even by the histological 
classification.
In conclusion, we report the results from the first 
pathobiology­driven, stratified, multicentre randomised 
trial in rheumatoid arthritis, which showed that although 
the histological classification of rheumatoid arthritis 
synovial tissue was insensitive in determining treatment 
response in the primary analysis RNA sequencing 
stratification had significant associations with clinical 
responses. Additionally, in patients with low or absent 
B­cell lineage expression signature (the target for 
rituximab) tocilizumab was superior to rituximab with 
regard to the number of patients with a CDAI50% or 
CDAI­MTR, and for most of the secondary outcomes.
In patients presenting with a B­cell rich synovium, 
rituximab was as effective as tocilizumab. These results 
suggest that disease tissue target expression concentrations 
are important to inform treatment response. However, 
because of the limitations of the study, the reported 
findings cannot justify a change in clinical practice. 
Nonetheless, replication of the results in independent 
trials (eg, the biopsy­driven Medical Research Council­
funded Stratification of Biologic Therapies for Rheumatoid 
Arthritis by Pathobiology trial; EudraCT 2017­004079­30), 
and the validation and refine ment of the RNA sequencing 
pathology classification (eg, using continuous variable 
data rather than a binary classification), might lead to the 
development of tests of clinical use for treatment allocation 
of specific targeted biological therapies—according to the 
corresponding target expression levels in the disease 
tissue—and towards precision rheumatology.15
The ability to target biological therapies to the right 
patients, rather than continue current practice of trial 
and error, might improve clinical response and early 
remission, with a major effect on disability and related 
health and societal costs while also reducing patient 
exposure to potentially toxic drugs. This would also align 
rheumatology practice with other disease in which the 
integration of molecular pathology into clinical algorithms 
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leads to treatment allocation according to drug target 
expression levels in the disease tissue as part of routine 
clinical practice.31
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